

Organized by:



In collaboration with:



Under the auspices of:



# IMMUNOTHERAPY bridge 2022

Naples, Italy  
November 30<sup>th</sup> - December 1<sup>st</sup>, 2022  
Royal Continental Hotel

# 2022

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING SECRETARIAT:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific sessions
- congress bags (badge, notepad, pen)
- coffee breaks and lunches from Nov 30<sup>th</sup> to Dec 1<sup>st</sup>

# GENERAL INFORMATION

## CONGRESS VENUE:


Royal Continental Hotel

Via Partenope, 38/44

80121 - Naples

+39 081 245 2068

<http://www.royalgroup.it/royalcontinental/it>



AIRPORT

RAILWAY  
STATION

CONGRESS  
VENUE

# SCIENTIFIC RATIONAL

---

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

# SCIENTIFIC PROGRAM

Wednesday, Nov 30<sup>th</sup>, 2022 | AUDITORIUM



10.00 am *Registration\*\**

10.40 am Introduction and objectives  
**Paolo A. Ascierto**

## **SITC SESSION CELL THERAPIES**

*Chairpersons: Lisa H. Butterfield, Marcela V. Maus*

10.45 am TCR-T, TILs and CAR-T  
**Daniel J. Powell**

11.00 am Engineered NK cells for cancer immunotherapy  
**Katy Rezvani**

11.15 am Biological drivers of CAR T cell failure  
**Nathan Singh**

11.30 am Biomarkers and immune cell subsets  
**Anne Monette**

11.45 am Best of SITC 2022 for clinical development and trials  
**Paolo A. Ascierto**

12.00 pm Discussion

12.30 pm **LECTURE - Breast Cancer**  
**Michelino De Laurentiis**

01.00 pm *Lunch\*\**

02.00 pm **SYMPOSIUM – What's new in Immunotherapy**

*Chairperson: Paolo A. Ascierto*

Renal Cell Carcinoma, **Camillo Porta**

Lung & Mesothelioma, **Alessandro Morabito**

New Immunotherapy options in Upper GI Cancer, **Sara Lonardi**

Discussion

# SCIENTIFIC PROGRAM

Wednesday, Nov 30<sup>th</sup>, 2022



## SESSION 2

### TRENDS IN IMMUNOTHERAPY

*Chairpersons:* **Bruno Daniele, Bernard A. Fox**

02:50 pm Interrogating microenvironment responses to neoadjuvant cancer immunotherapy  
**Robert L. Ferris**

03:05 pm Immunotherapy data in GU Cancers: what's new and what's confirmed  
**Sergio Bracarda**

03:20 pm Colorectal Cancer  
**Antonio Avallone**

03:35 pm Translating novel immunotherapy combinations in GI Cancer  
**Gregory B. Lesinski**

03:50 pm Breast cancer immunotherapy: moving forward  
**Leisha A. Emens**

04:05 pm Progress in Immunotherapy for Ovarian Cancer  
**Kunle Odunsi**

04:20 pm Trends in lymphoma immunotherapy and lessons for solid tumors  
**Joshua Brody**

04:35 pm Discussion

05:05 pm *Coffee break\*\**

## GREAT DEBATE SESSION

*Chairpersons:* **Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov**

05:20 pm Can computational biology approach improve clinical trial design? Yes or no  
**Samir N. Khleif, Robert A. Beckman**

05:50 pm Discussion

06:00 pm Cell therapy for solid tumors: yes or no?  
**Renier Brentjens, Kunle Odunsi**

06:30 pm Discussion

# SCIENTIFIC PROGRAM

Thursday, Dec 1<sup>st</sup>, 2022



## SESSION 3

### DRIVERS OF IMMUNE RESPONSES

*Chairpersons: Alfredo Budillon, Luigi Buonaguro*

- |          |   |
|----------|---|
| 09:30 am | Immunogenicity and therapeutic cross-protection to NRAS Q61 public neoantigens<br><b>Christopher A. Klebanoff</b>   |
| 09:45 am | Intracranial administration of immune checkpoint blockade in patients with recurrent glioblastoma<br><b>Bart Neyns</b>  |
| 10:00 am | Bispecific antibodies in cancer immunotherapy<br><b>Omid Hamid</b>  |
| 10:15 am | Harnessing novel CD4 T cell-based therapies against solid tumors<br><b>Chrystal M. Paulos</b>   |
| 10:30 am | Therapeutic strategies to activate innate immunity in prostate cancer<br><b>Akash Patnaik</b>   |
| 10:45 am | Targeting neutrophils to enhance antitumor immunity<br><b>Brahm Segal</b>   |
| 11:00 am | <i>Coffee break**</i>   |
| 11:15 am | New clinical data with novel immune checkpoints<br><b>Tomas Kirchhoff</b>   |
| 11:30 am | Mechanisms of ICI toxicities across tumor types<br><b>Ryan J. Sullivan</b>  |
| 11:45 am | Long-term toxicity and the impact on quality of life<br><b>Douglas B. Johnson</b>   |
| 12:00 pm | Evidence for adapting radiotherapy to immune checkpoint blockade<br><b>Silvia Chiara Formenti</b>   |
| 12:15 pm | Enhancing clinical genomics datasets with multimodal EHR data and imaging<br><b>Carlo Bifulco</b>   |
| 12:30 pm | Discussion  |
| 12:45 pm | <b>SYMPOSIUM - Non Melanoma Skin Cancer</b><br>Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC<br><b>Paolo A. Ascierto, Dirk Schadendorf</b> |
| 01:35 pm | <i>Lunch**</i>  |

# SCIENTIFIC PROGRAM

Thursday, Dec 1<sup>st</sup>, 2022



## **GREAT DEBATE SESSION**

*Chairpersons:* **Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov**

02:35 pm Periphery/blood biomarkers VS TME biomarkers  
**Ryan J. Sullivan, Samir N. Khleif**

03:05 pm Discussion

03:15 pm CAR-T vs CAR-T NK  
**Marco Ruella, Katy Rezvani**

03:45 pm Discussion

## **SESSION**

### **NEOADJUVANT IMMUNOTHERAPY**

*Chairpersons:* **Paolo A. Ascierto, Elizabeth M. Burton**

03:55 pm NSCLC  
**Tina Cascone**

04:10 pm Immunotherapy for High-Risk Early TNBC  
**Leisha A. Emens**

04:25 pm Non melanoma skin cancer  
**Neil D. Gross**

04:40 pm Pan-Tumor application of immune-related Pathologic Response Criteria (irPRC)  
**Tricia Cottrell**

04:55 pm Colon Cancer  
**Myriam Chalabi**

05:10 pm Personalization of neoadjuvant immunotherapy in melanoma  
**Christian Blank**

05:25 pm Discussion

05:55 pm Conclusions  
**Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov**

# PRESIDENCY

---

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

# SCIENTIFIC BOARD

**Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory; Director, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Elizabeth M. Burton**

Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

**Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

**Corrado Caracò**

Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Mary Dean**

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# SCIENTIFIC BOARD

---

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Claus Garbe**

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin**

Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

**Iman Osman**

Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Tara Withington**

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# FACULTY

---

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Antonio Avallone**

Unit of Abdominal Medical Oncology, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Robert A. Beckman**

Professor of Oncology and Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center, Innovation Center of Biomedical Informatics, Georgetown University Medical Center, Washington, DC, US

**Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam; Medical Oncology, Leiden University Medical Center (LUMC), Leiden, Netherlands

**Sergio Bracarda**

Director, Department of Oncology and Medical & Translational Oncology Unit, Santa Maria Hospital, Terni, Italy

**Renier Brentjens**

Deputy Director & Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Joshua Brody**

Director, Lymphoma Immunotherapy Program, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, US

**Alfredo Budillon**

Scientific Director, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

**Luigi Buonaguro**

Director Innovative Immunological Models Unit, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

**Elizabeth M. Burton**

Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

**Tina Cascone**

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Myriam Chalabi**

Medical Oncologist, GI cancers, Netherlands Cancer Institute, Amsterdam, Netherlands

**Tricia Cottrell**

Assistant Professor, Queen's Cancer Research Institute, Kingston, Ontario, Canada

**Bruno Daniele**

Director, Oncology Unit, "Ospedale del Mare" Hospital, Naples, Italy

**Michelino De Laurentiis**

Director of SC Experimental Oncology Clinic of Senology; Director of the Corp-S Department for Research of Oncology Pathways of the Toracic District, IRCCS Fondazione "G. Pascale", Naples, Italy

# FACULTY

---

**Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

**Robert L. Ferris**

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research Center, Professor of Otolaryngology, of Immunology, and of Radiation Oncology, University Pittsburgh School of Medicine, PA, US

**Silvia Chiara Formenti**

Chairman of the Department of Radiation Oncology, Weill Cornell Medicine; Associate Director of the Meyer Cancer Center, Radiation Oncologist in Chief, New York-Presbyterian Hospital, New York, NY, US

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Neil D. Gross**

Professor and Director of Clinical Research, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Douglas B. Johnson**

Associate Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, US

**Samir N. Khleif**

Director of the Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

**Tomas Kirchhoff**

Associate Professor, Department of Population Health, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

**Christopher A. Klebanoff**

Memorial Sloan Kettering Cancer Center, New York, NY; The Parker Institute for Cancer Immunotherapy, San Francisco, CA, US

**Gregory B. Lesinski**

Professor, Vice Chair for Basic Research, Department of Hematology & Medical Oncology, Associate Director for Basic Research, Co-Director, Translational GI Malignancy Program, Winship Cancer Institute of Emory University, Atlanta, GA, US

**Sara Lonardi**

Chief of Gastrointestinal Cancers Unit, Veneto Institute of Oncology - IRCCS, Padova, Italy

**Marcela V. Maus**

Associate Professor of Medicine, Harvard Medical School; Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, MA, US

**Anne Monette**

Senior Research Associate, Lady Davis Institute for Medical Research; Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada

# FACULTY

---

**Alessandro Morabito**

Director of Thoracic Medical Oncology, National Cancer Institute, IRRCS "Fondazione G. Pascale", Naples, Italy

**Bart Neyns**

Head of Department Medical Oncology, Universitair Ziekenhuis (UZ) Brussel; Clinical Professor at the Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium

**Kunle Odunsi**

Director, University of Chicago Medicine Comprehensive Cancer Center; Dean for Oncology, Biological Sciences Division, The University of Chicago, Chicago, IL, US

**Akash Patnaik**

Director, Laboratory for Prostate Cancer Developmental Therapeutics/ImmunoOncology Attending Physician, Genitourinary Oncology Program University of Chicago Comprehensive Cancer Center Chicago, IL, US

**Chrystal M. Paulos**

Associate Professor, Department of Surgery / Microbiology & Immunology, Director of Translational Research, Cutaneous Malignancies, Winship Cancer Institute at Emory University Atlanta, GA, US

**Camillo Porta**

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro"; Chief, Division of Medical Oncology, AOU Policlinico Consortziale, Bari, Italy

**Daniel J. Powell**

Associate Professor of Pathology & Laboratory Medicine; Scientific Director of Immunotherapy in the Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Katy Rezvani**

Sally Cooper Murray Chair in Cancer Research, Professor of Medicine, Chief, Section of Cellular Therapy, Director, Cell Engineering GMP Lab, Executive Director, Adoptive Cell therapy Platform, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Marco Ruela**

Assistant Professor of Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

**Dirk Schadendorf**

Director, Clinic for Dermatology, University Hospital Essen, Essen, Germany

**Brahm Segal**

Chair, Department of Internal Medicine, Chief, Division of Infectious Diseases, Professor of Oncology, Member, Department of Immunology, Roswell Park Comprehensive Cancer Center; Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, US

**Nathan Singh**

Assistant Professor, Department of Medicine, Oncology Division, Stem Cell Biology, Washington University in St. Louis, St. Louis, MO, US

**Ryan J. Sullivan**

Associate Professor of Medicine, Harvard Medical School; Associate Professor of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, US

## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Immunotherapy Bridge Congress has been accredited (ID CME 327-365182) with 4,2 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and Gender medicine", belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses, pediatric nurse.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day);
2. Complete the evaluation form at the end of the Congress.

CME certificate will be sent at the end of the validation procedure.

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

**IT IS HIGHLY RECOMMENDED TO WEAR A FFP2 MASK TO ATTEND THE CONGRESS**

\_\_\_\_\_

Immunotherapy Bridge is sponsored by an unrestricted grant from:

---

PLATINUM SPONSOR

SANOFI GENZYME  | **REGENERON**

GOLD SPONSOR

 Bristol Myers Squibb™

SILVER SPONSOR

 **MSD**

SPONSOR

**MERCK** 

 Roche

  
SUN  
PHARMA